Format

Send to

Choose Destination
Curr Opin Mol Ther. 2006 Dec;8(6):529-38.

Drug evaluation: the C5a receptor antagonist PMX-53.

Author information

1
Cincinnati Children's Hospital Research Foundation, Division of Molecular Immunology, MLC 7021, Cincinnati, OH 45229, USA. Joerg.Koehl@chmcc.org

Abstract

Peptech is developing PMX-53, a complement C5a inhibitor for the potential treatment of inflammatory disorders, including rheumatoid arthritis and psoriasis. Phase Ib/IIa clinical trials have been completed for both indications.

PMID:
17243489
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center